# Urinary Bladder Neoplasms FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/urinary-bladder-neoplasms

> 4 upcoming FDA catalysts in urinary Bladder Neoplasms: Gemzar (gemcitabine, JNJ) on Dec 2026 to Mar 2027 (topline data readout); Gemzar (gemcitabine, JNJ) on December 2026 (primary completion); KEYTRUDA® (pembrolizumab, MRK) on Jan to Apr 2027 (topline data readout); KEYTRUDA® (pembrolizumab, MRK) on January 2027 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| July 3, 2025 | [TAR-200 primary completion](https://sec-api.dev/pdufa/tar-200) | JNJ | Urinary Bladder Neoplasms | completed | "NCT04640623 (A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-07-03 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC; Results First Posted 2026-07-29." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04640623)) |
| July 29, 2026 | [TAR-200 topline data readout](https://sec-api.dev/pdufa/tar-200) | JNJ | Urinary Bladder Neoplasms | completed | "NCT04640623 (A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-07-03 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC; Results First Posted 2026-07-29." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04640623?tab=results)) |
| Dec 2026 to Mar 2027 | [Gemzar (gemcitabine) topline data readout](https://sec-api.dev/pdufa/gemcitabine) | JNJ | Urinary Bladder Neoplasms | scheduled | "NCT04658862 (A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04658862)) |
| December 2026 | [Gemzar (gemcitabine) primary completion](https://sec-api.dev/pdufa/gemcitabine) | JNJ | Urinary Bladder Neoplasms | scheduled | "NCT04658862 (A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04658862)) |
| Jan to Apr 2027 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Urinary Bladder Neoplasms | scheduled | "NCT04241185 (Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-31 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04241185)) |
| January 2027 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Urinary Bladder Neoplasms | scheduled | "NCT04241185 (Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-31 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04241185)) |

## Drugs

- [TAR-200](https://sec-api.dev/pdufa/tar-200) (JNJ)
- [Gemzar (gemcitabine)](https://sec-api.dev/pdufa/gemcitabine) (JNJ)
- [KEYTRUDA® (pembrolizumab)](https://sec-api.dev/pdufa/pembrolizumab) (MRK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/urinary-bladder-neoplasms.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Urinary Bladder Neoplasms FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/urinary-bladder-neoplasms

```bibtex
@misc{secapidev_indications_urinary_bladder_neoplasms_20261116,
  title        = {Urinary Bladder Neoplasms FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/urinary-bladder-neoplasms}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_urinary_bladder_neoplasms_20261116","title":"Urinary Bladder Neoplasms FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/urinary-bladder-neoplasms","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
